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Mistletoe preparations such as Iscador are in common use as complementary/anthroposophic
medications for many cancer indications, particularly for solid cancers. The efficacy is still
discussed controversially. This paper presents an individual patient data meta-analysis of all
published prospective matched-pair studies with breast cancer patients concerned with long-
term application of a complementary/anthroposophic therapy with the mistletoe preparation
Iscador. Six sets of data were available for individual patient meta-analysis of breast cancer
patients, matched according to prognostic factors into pairs with and without mistletoe
(Iscador) therapy. The main outcome measures were overall survival and psychosomatic self-
regulation. Overall survival was almost significant in favor of the Iscador group in the
combined data set of the randomized studies: estimate of the hazard ratio with 95% confidence
interval 0.59 (0.34, 1.02). Overall survival was highly significant in the combined data set of the
non-randomized studies: 0.43 (0.34, 0.56). In the combined analysis of the randomized studies,
improvement of psychosomatic self-regulation, as a measure of autonomous coping with the
disease, was highly significant in favor of the Iscador group: estimate of the median difference
0.45 (0.15, 0.80), P=0.0051. The analyzed studies show that therapy with Iscador might
prolong overall survival and improve psychosomatic self-regulation of breast cancer patients.
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Background
In Europe, many women with breast cancer take comple-
mentary therapies, however, evidence of its efficacy on
disease progression and survival is still a topic of contro-
versial discussion (1). Among the complementary thera-
pies used by breast cancer patients, the aqueous extracts
of European mistletoe (Viscum album L.), developed on
the basis of anthroposophic medicine, are the most
frequently used medications, particularly in German
speaking countries (2,3).
The following report describes an individual patient
data meta-analysis (4,5) of all available data concerning
breast cancer therapy with the mistletoe preparation
Iscador and with the outcomes survival and psychosomatic
self-regulation: two randomized and four non-randomized
matched-pair studies (6–9). In such an analysis, not the
statistical summaries and estimates from the original
publications are used, but the raw data from the original
studies are pooled and evaluated together.
The three special design features of the studies analyzed
below were the matched pairs, the long-term follow-up
and the parallel implementation of prospective cohort
studies and randomized trials. In addition to the specific
outcomes, these features makethem different from all other
prospective controlled studies (10,11) concerning Iscador
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properly cited.therapy for breast cancer (12–22). Under these circum-
stances, the results of both randomized and non-rando-
mized matched-pair studies can be compared and hence
come with a more reliable internal validity due
to randomization (given comparable results), which is
enriched by the more reliable generalizability of the non-
randomized cohorts (23).
Patients and Methods
For more details concerning the background, initial data
assessment, the quality of life measurement with psycho-
somatic self-regulation, the observed therapy and inter-
vention, the patients, the matching process for both
randomized and non-randomized studies, the method of
exclusion of pairs and the follow-up until 1998, we refer
to the original papers (6–8) and the re-analysis (9) of the
breast cancer data sets (6).
Psychosomatic Self-regulation
Quality of life was assessed in these studies as the degree
of psychosomatic ‘self-regulation’. This term applies to
intrinsic activities of a human being through which he or
she achieves well-being, inner equilibrium, appropriate
stimulation, a feeling of competence and a sense of
being able to control stressful situations (6,24–28).
Self-regulation is assessed by a self-administered question-
naire and measured on a scale from 1 (low) to 6 (high). Self-
regulation influences the incidence and course of cancer.
Studies covering a 27-year period and involving 35814
participants (29) showed a higher incidence of cancer
in those with poor self-regulation, revealing detrimental
synergies between low self-regulation and other cancer risk
factors (29,30). In patients with manifest cancer, higher
self-regulation correlated with longer survival (29,30).
Objectives
The main objective of this individual patient data meta-
analysis was the evaluation of the overall survival of long-
term therapy with Iscador in addition to conventional
oncological treatment in patients with primary breast
cancer of different stages, compared with standard treat-
ment alone. Survival is measured from the year of first
diagnosis until death for any reason (except certified non-
tumor-related accidents and suicides). In both randomized
studies, psychosomatic self-regulation as a measure of
autonomous coping with the disease was assessed twice;
hence it can be analyzed, whether a therapy with Iscador,
in addition to conventional oncological treatment,
improves psychosomatic self-regulation in patients with
breast cancer in comparison with standard treatment alone.
Designs of Evaluated Studies
All studies to be evaluated here were controlled cohorts and
wereprospectivebydesign,thatis,allbreastcancerpatients
that were included in this research were recruited beginning
in 1971, assessed, matched according to pre-specified
relevant prognostic factors and followed up during their
life time. The final follow-up happened during 1998.
The matching criteria included: tumor stage at first
diagnosis for one of the four diagnostic groups (‘first
diagnosis’), status of menopause at first diagnosis, year of
first diagnosis of the breast cancer stage with up to 3 years
difference (data not shown), age at first diagnosis with up
to 3 years difference and type of conventional therapy.
For details of the matching procedure, the randomization
technique and the exclusion of pairs please refer to the
original papers (6,8).
In the randomized studies, the data pool for building
matched-pairs consisted of breast cancer patients that had
never received mistletoe therapy. After randomization it
was suggested to one partner of each pair to ask their
attending physician (who had no part in the recruitment,
selection and matching process) to prescribe them com-
plementary Iscador therapy. If this suggestion was taken
up, the pair was included.
In the case of non-randomized studies, if a matching
partner could be found within the data base according to
the above criteria for each Iscador patient of one of the
stage groups, the pair was included.
Patients were followed-up by a team of scientific resear-
chers working for the Institute of Preventive Medicine
(Heidelberg). Up to 1998, they made periodically from 1 to
several months standardized telephone interviews or home
visits performing structured interviews using in each case
predetermined case report forms. In the final follow-up
during 1998 any dates and causes of death not yet regis-
tered were determined from the local resident’s registration
offices (‘Einwohnermeldeamt’) and from the local boards
of health (‘Gesundheitsamt’).
Data Sets
The combined data set MAMMARAND (255 patients)
for the meta-analysis concerns the final raw data from
the following randomized matched-pair studies (Table 1):
MammaRand:( 2 38 patients): primary breast cancer
patients with no recurrences of the primary tumor, no
lymphatic and no distant metastases (8); MammaLym
Rand (217 patients): primary breast cancer patients
with only lymphatic metastases and no recurrences (6,9).
The combined data set MAMMA (2264 patients) for
the meta-analysis concerns the final raw data from the
following non-randomized matched-pair studies (Table 1):
Mamma (284 patients): primary breast cancer with no
recurrences of the primary tumor, no lymphatic and no
distantmetastases(8);MammaRec(242patients):primary
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primary tumor and no lymphatic or distant metastases (6);
MammaLym (255 patients): primary breast cancer
patients with only lymphatic metastases (6); MammaMet
(283 patients): primary breast cancer patients with
distant metastases (6).
Subsets of Original Data Sets
A patient group of pairs with ‘strict matching’ is a sub-
group of all matched-pairs of patients fulfilling exactly all
matching criteria. A patient group with a ‘balanced set’ is
a subgroup of all matched-pairs of patients, where pairs
with prognostic factors favoring patients with Iscador
therapy were eliminated; they lie in between the complete
data set and the set with strict matching. In the individual
patient data meta-analysis, these different data sets were
combined into sets of pairs with ‘strict matching’ and
‘balanced sets’, respectively (see Table 4).
Statistics
In the first stage of the meta-analysis of overall survival,
the means and medians of the times estimated according
to Kaplan-Meier were calculated. In addition, the log-
rank statistic was used, including stratification according
to the matched-pairs (31). All P-values are two-sided.
In order to explore the sensitivity of the matching criteria
in the combined non-randomized studies, the complete
data set was compared with the balanced set and the strictly
matched set.
In the second stage of the meta-analysis of overall
survival, the Cox proportional hazard (PH) regression
model was applied to the combined complete data sets
from the non-randomized matched-pairs studies.
Stratification according to matched-pairs was applied,
that is, we performed a conditional analysis accounting
for matching. This generally produces a conservative
estimate compared with the unmatched analysis (32)
(§ 7.1). In addition, a stratification according to the
individual data sets (see above) was applied. The model
development and the assessment of model adequacy were
performed according to recommendations (33,34). An
automatic variable selection procedure was not used. An
adjustment of prognostic factors in the combined analysis
of the randomized studies was not performed. According
to the recommendations (34) the assumption of PH was
checked statistically and graphically; if any one, but not
both, of these methods fails to show a positive result, we
say that the PH assumption is ‘moderately fulfilled’.
Confidence intervals (CI) are always 95% CI and test
results were judged as significant, if P<0.05. The
statistical analyses were performed using S-Plus 7.0 for
Windows Professional Edition (Insightful Corp. 2005,
Seattle, WA, USA). The Wilcoxon paired sample (WPS)
tests, the Hodges-Lehmann estimates (35) and the mar-
ginal homogeneity tests were calculated for n<100 using
the exact procedures from StatXact 7 (Cytel Software
Corporation 2005, Cambridge, MA, USA).
Results
Patient Characteristics for Combined Randomized
Matched-pair Studies (Table 2)
MAMMARAND (n=255, Table 2)
The matching was perfect for the variables stage (FIGO,
TNM) and grading. Concerning therapies, there were some
minor differences in operation, chemotherapy and radio-
therapy and larger differences in the case of hormone
therapy. Most differences, particularly in the case of
Table 1. Studies of patients with breast cancer and Iscador therapy in matched-pair design
Design Study Indication Pairs of patients Published
Recruited Therapy
declined
or not
received
Drop-out
after start
of therapy
Lost to
follow-up
Matching
criteria not
fulfilled
Final
Randomized
matched-pairs
MammaRand Breast cancer without
recurrences or metastases
59 19 0 2 5 38 (8)
MammaLymRand Breast cancer with
lymphatic metastases
17 0 0 0 0 17 (6,9)
MAMMARAND Breast cancer 76 19 0 2 5 55
Non-randomized
matched-pairs
Mamma Breast cancer without
recurrences or metastases
105 2 0 6 13 84 (8)
MammaRec Breast cancer with only
local recurrences
50 5 0 2 1 42 (6,9)
MammaLym Breast cancer with
lymphatic metastases
64 7 0 1 1 55 (6,9)
MammaMet Breast cancer with
distant metastases
90 2 0 3 2 83 (6,9)
MAMMA Breast cancer 309 16 0 12 17 264
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in favor of the control group, i.e. patients of the control
group had on average more of these therapies than those of
the Iscador group. However, since these were randomized
matched-pairs, there is no reason to believe that this leads
to a systematic bias. Self-regulation at baseline was not
matched; the difference between the therapy groups was
not significant (WPS-test, P=0.51).
Patient Characteristics for Combined Non-randomized
Matched-pair Studies (Table 3)
Three sets were analyzed and compared in the sensitivity
analysis: (i) combined complete data sets, (ii) combined
balanced data sets: exclusion of pairs, the risk factors of
which were in favor of the mistletoe patient, (iii) combined
reduced data sets consisting of all pairs with strict matching
Table 2. Distribution of patient characteristics of the combined study
MAMMARAND
Prognostic
variables
MAMMARAND WPS
Iscador Control P
n=55 n=55
Matching
variables
FIGO TNM
I T1aN0M0 23 23
IIA T2N0M0 7 7
IIB T3N0M0 8 8
IIIA T2N2M0 1 1
T3N1–2M0 5 5
IIIB T4N1–4M0 10 10
T3N3M0 1 1
Grading
12 6 2 6
23 3
34 4
NA 22 22
Menopause
Prae 12 12
post 5 5
NA 38 38
Age at first diagnosis
Mean 50.22 50.31
SD 7.56 7.69
Range 33–63 34–62
Conventional therapy
Operation 55 54
Chemotherapy 24 25
Radiotherapy 25 27
Hormone therapy 9 16
Baseline
variable
Self-regulation 0.51
Mean/median 3.63/3.70 3.54/3.60
SD 0.80 0.76
Range 1.7–5.5 1.7–5.5
Therapy
variable
Iscador use (years)
Mean/median 8.47/7.00 NA
SD 5.84
Range 0.08–20.83
Abbreviations: WPS, Wilcoxon paired sample test; SD, standard
deviation; NA, not available.
Table 3. Distribution of patient characteristics of the combined study
MAMMA
Prognostic
variables
MAMMA Test
Iscador Control P
n=264 n=264
Matching
variables
FIGO TNM 0.99
b
I T1N0M0 53 53
IIA T2N0M0 25 26
IIB T3N0M0 32 31
T2N1M0 3 3
III T4N0M0 16 16
IIIA T2N2M0 5 5
T3N2M0 5 5
IIIB T1-3N3M0 6 6
T4N1-4M0 36 36
IV TXNXM1 83 83
Menopause 0.99
a
Prae 28 26
Post 121 123
NA 115 115
Age at first diagnosis 0.97
c
Mean 54.86 54.84
SD 8.40 8.51
Range 32–70 29–70
Conventional therapy
Operation 264 264 0.99
a
Chemotherapy 133 118 <0.01
a
Radiotherapy 133 135 0.82
a
Hormone therapy 92 90 0.79
a
Baseline
variable
Self-regulation <0.01
c
Mean/median 3.87/4.00 3.47/3.55
SD 1.19 1.01
Range 1.0–6.0 1.0–6.0
Therapy
variable
Iscador use (years) NA
Mean/median 4.62/3.00
SD 4.66
Range 0.08–23.83
Abbreviations: SD, standard deviation; NA, not available:
aMN,
McNemar test;
bMH, Marginal homogeneity test;
cWPS, Wilcoxon
paired sample test.
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from the strict matching within the groups (i) and (ii) can
be found in the literature (8,9).
MAMMA (Table 3)
For the complete set (n=2264), the difference in the
stages and in the status of menopause between the two
groups was not significant (MH-test, P=0.99).
Concerning therapies, differences in chemotherapy were
judged as relevant, which was also significant (MN-test,
P=0.007) in favor of the Iscador group. For radio-
therapy, the situation was judged as balanced (MN-test,
P=0.82). Concerning age at first diagnosis, the differ-
ence was not significant (WPS-test, P=0.97).
On this basis, 38 pairs had to be eliminated since the
Iscador patients seemed to be favored by the distribution
of the prognostic factors, in particular chemotherapy, in
the end producing a balanced set of 226 pairs. Strict
matching, i.e. with no exceptions in all matching var-
iables, produced 144 pairs. Psychosomatic self-regulation
at baseline was not matched; the difference between the
therapy groups in the first evaluation of self-regulation
was significant (WPS-test, P=0.0005).
Overall Survival
Overall survival was analyzed for all data sets in
four ways (see Tables 3 and 4): (i) descriptive analysis;
(ii)stratifiedlog-ranktestonthebasisofthematched-pairs;
(iii) randomized matched-pairs studies: Cox PH model with
no adjustment for other variables than Iscador therapy;
(iv) non-randomized matched-pairs studies: Cox PH model
fitted to all available prognostic factors with subsequent
retrospective elimination and assessment of model
adequacy.
The data set MAMMARAND that combines the data
sets MammaRand and MammaLymRand, was analyzed in
full descriptively (stratified log-rank test, P=0.057) and
with a Cox PH models: estimate of the hazard ratio with
95% CI: 0.59 (0.34, 1.02), PH assumption moderately
fulfilled (Table 4, Fig. 1). In the individual randomized
studies, MammaRand (censored values in 16 patients) and
MammaLymRand (no censored values), however, the
effects were not significantly in favor of the Iscador
therapy (Tables 4, 5). Since there were no censored
survival times in MammaLymRand, and the PH assump-
tion was definitely not fulfilled for this data set, we
calculated an estimate of the median of the pair wise
differences of the survival times Iscador versus control:
2.5 (0.83, 4.50), P=0.018, with the Hodges–Lehmann
procedure, which produced a significant result.
In a similar fashion, the data set MAMMA, which com-
bines the data sets Mamma, MammaRec, MammaLym and
MammaMet, was analyzed descriptively and with a Cox
PH model. It turned out that the PH assumption in the
adjusted model was moderately fulfilled; this model
Table 4. Descriptive statistics of survival
Study Set
a Pairs Mean Median Stratified log rank test
Iscador Control Iscador Control
MammaRand Complete set 38 14.7 13.8 14.8 14.3 0.194
MammaLymRand Complete set 17 4.79 2.41 6.25 2.33 0.134
MAMMARAND Complete set 55 11.7 10.3 11.3 10.8 0.057
Mamma Complete set 84 12.1 10.3 11.8 10.1 0.0002
Balanced set 73 11.93 9.98 11.8 10.0 <0.0001
Strict matching 24 11.21 9.55 11.0 10.2 0.221
MammaRec Complete set 42 6.52 5.45 5.17 4.83 0.0079
Balanced set 39 5.90 5.35 5.17 4.83 0.0231
Strict matching 29 6.08 4.44 5.17 4.33 0.0025
MammaLym Complete set 55 4.63 3.11 4.33 3.17 0.0004
Balanced set 42 3.88 3.05 3.92 3.17 0.0423
Strict matching 38 3.86 2.97 4.04 3.17 0.0516
MammaMet Complete set 83 3.56 2.51 3.33 2.25 0.0007
Balanced set 72 3.27 2.36 3.08 2.17 0.0095
Strict matching 53 3.42 2.38 3.08 2.17 0.0056
MAMMA Complete set 264 6.98 5.57 5.08 3.58 <0.0001
Balanced set 226 6.63 5.47 4.83 3.58 <0.0001
Strict matching 144 5.37 4.15 4.33 3.21 <0.0001
aGroups with a ‘balanced set’ form subgroups of complete sets of matched-pairs not favoring the patients with Iscador therapy; groups with ‘strict
matching’ form subgroups of complete sets of matched-pairs of patients fulfilling exactly all matching criteria.
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The hazard ratio estimate measures the Iscador versus the control group and the P-value from the Wald test measures the significance of the
estimated variable Iscador treatment (PH, proportional hazards, see Statistics section). In MAMMA there is 1 pair with a missing value in the
variable self-regulation, and there are no significant interactions; the only significant adjustment factor is self-regulation (P<0.001) measured at
initial data assessment.
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Figure 1. (A) MammaRand; (B) MammaLymRand and (C) MAMMARAND: Kaplan–Meier survival curves for the complete sets.
162 Therapy of breast cancer patients with Iscadorproduces a highly significant result: 0.43 (0.34, 0.56),
P<0.0005 (Table 5, Fig. 2). The stratified log-rank test
gives P<0.0001 in all three cases (complete set, balanced
set, strict matching, Table 4). In Fig. 2, the majority of all
patients (73.5%) have survival times below 8 years; hence
the first third of the figure is the most relevant part. The
results of the individual non-randomized studies Mamma,
MammaRec, MammaLym and MammaMet mirror these
effects and show at least positive trends in favor of the
Iscador group and in most cases highly significant results.
Self-regulation
Psychosomatic self-regulation was only assessed twice
for the data sets MammaRand, MammaLymRand and
Mamma. The second assessment for Mamma and Mamma
Rand took place 12 months after initial data assessment
(in the form of a structured personal interview with
standardized checklists) and for MammaLymRand 3
months after initial data assessment. For the two rando-
mized sets of matched-pairs MammaRand and Mamma
LymRand, the complete sets of both sets individually and
combined were analyzed by the WPS-test together with the
Hodges–Lehmann procedure estimating the median of the
pair wise differences of the second versus the first
evaluation of self-regulation: 0.35 (0.05, 0.60)
(P=0.034), 0.90 (0.00, 1.75) (P=0.055), combined 0.45
(0.15, 0.80) (P=0.0051). For Mamma, the WPS-test was
applied to the complete set, the balanced set and the set
with strict matching: 0.20 (0.00, 0.35) (P=0.031), 0.15
(0.00, 0.35) (P=0.055) and 0.30 (0.05, 0.60) (P=0.014),
respectively. Hence nearly all studies show significant
improvements or at least strong trends: Iscador therapy
might have had helped to improve psychosomatic self-
regulation of breast cancer patients, as a measure of
autonomous coping with the disease.
Discussion
Design and Analysis
An integrative approach was chosen to evaluate the
complex interplay of factors that may influence the
prognosis of cancer in real life, i.e. a combination of non-
randomized controlled epidemiological studies with ran-
domized intervention trials within the same cohort. Using
this approach, the results of randomized trials with high
internal validity (reliability results) can be integrated into
the results of non-randomized studies with, in general,
high external validity (generalizability). For this reason,
we attempted to add a randomized intervention trial for
the same indication and from the same cohort of patients
for every cancer indication investigated by a non-
randomized controlled epidemiological study. However,
due to financial and logistical constraints, this was only
possible in the stage groups of breast cancer without
lymphatic and distant metastasis and breast cancer with
only lymphatic metastases.
The reason for applying different types of analysis is to
demonstrate the strength or the sensitivity of the results
against different sets of constraints. Particularly, non-
randomized studies are susceptible to different types of
biases (36) that can be dealt with, to a certain extent, by
comparing the results of different statistical approaches.
Randomized Matched-pairs
Overall, the results of the data set MAMMARAND, which
combines the randomized matched-pairs studies Mamma
Rand (breast cancer without recurrences and without meta-
stases, 38 pairs) and MammaLymRand (breast cancer with
only lymphatic metastases, 17 pairs), show at least strong
positive trends in favor of the long-term complementary
Iscador therapy versus conventional treatment alone.
Concerning overall survival, the individual patient data
meta-analysis for all randomized matched-pairs was almost
significant in favor of the Iscador group in the descriptive
analysis (log rank test, P=0.057) as well as in the Cox
model [estimate for hazard ratio: 0.59 (0.34, 1.02)].
Concerning the short-term improvement of psychoso-
matic self-regulation, the combined data set MAMMA
RAND shows significant improvements: estimate of the
median difference 0.45 (0.15, 0.80). In MammaLymRand
the estimate of the median of improvement was 0.9 on a
scale from 1 to 6. As there was no significant difference
in the baseline values in MAMMARAND (Table 2), also
minor improvements with respect to the Iscador group
might be of some clinical relevance (25).
Non-randomized Matched-pairs
Overall, the results of the data set MAMMA that com-
bines the non-randomized studies Mamma, MammaRec,
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Figure 2. Adjusted survival curves for MAMMA based on the model
from Table 5 (MAMMA has 264 matched-pairs with 1 pair having a
missing value in the variable self-regulation. The adjusted variable is
complete self-regulation; there are no significant interactions; the PH
assumption is moderately fulfilled).
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in favor of the Iscador group in all cases.
Particularly, when concerning overall survival, all
results of the unadjusted evaluations were significantly
in favor of the Iscador group (Table 4). This compares
well with the corresponding adjusted Cox PH model of
MAMMA with the following estimate for hazard ratio:
0.43 (0.34, 0.56) (Table 5). In this case, self-regulation
was a significant (P<0.001) predictor of the outcome
and included in the model, therefore.
For the different subsets, the unadjusted analyses show
comparable results (Table 4), proving that the original
sets were fairly well balanced across the different therapy
groups, at least with respect to the prognostic factors
used in the matching process. This is supported by the
fact that the results of the Cox PH model in most indi-
vidual studies do not differ very much between adjusted
and unadjusted analyses [Table 5, details in (8,9)]. Also,
in the combined set MAMMA, the results of the unad-
justed analysis for the hazard ratio was 0.42 (0.33, 0.55),
which is very close to the above mentioned value.
Consistency and Generalizability
The baseline values and the results of the randomized
matched-pair trial MammaRand and the non-randomized
matched-pair study Mamma were well comparable (8)
(Tables 3 and 4). That is, although not significant in all
cases, the results of the randomized trial MammaRand
were consistent with the results of Mamma: they point in
the same direction. Together, both studies gain from each
other: the first has the stronger validity and the latter the
stronger generalizability.
For MammaLymRand and MammaLym, the situation
is more complex. The patients from the latter were 15
years older at the time of first diagnosis and have a much
higher level of self-regulation (9) (Tables 3 and 4). Still,
the results for survival in MammaLymRand as well as for
MammaLym were convincing in favor of Iscador therapy.
The results of the combined data sets MAMMARAND
and MAMMA also point in the same direction and could
be interpreted as complementing each other.
For survival of breast cancer patients of all stages,
particularly without metastases, there is evidence from
other controlled studies in favor of mistletoe therapy,
particularly Iscador (12,37). In addition, research based
on archival data show a significant advantage for Iscador
therapy on survival (38,39).
Concerning the short term effects of Iscador therapy
on psychosomatic self-regulation of breast cancer
patients, the results of the randomized trials Mamma
Rand, MammaLymRand and their combined data set
MAMMARAND, as well as those of the non-randomized
study Mamma, were highly consistent. They compare well
with other randomized trials on the effect of mistletoe
therapy on the overall quality of life of breast cancer
patients (13,40,41). In addition, two recently published
non-randomized controlled studies with Iscador therapy
in addition to conventional therapy versus conventional
therapy alone show similar effects (15,16).
Causality
The question certainly arises, whether the reported asso-
ciations in the non-randomized matched-pairs studies
between survival and therapy with the mistletoe prepara-
tion Iscador were effects of unknown origin or causally
related to this therapy. The foregoing considerations show
that these effects were not spurious: they were significant in
nearly all cases. Although bias and confounding cannot be
ruled out in non-randomized studies, the consistent results
of the randomized trials and the non-randomized parallel
studies suggest a residual effect that is due to the therapy
with Iscador alone.
The main conditions of the causal character of an asso-
ciation include (42–45): (i) strong association, (ii) temporal
sequence, (iii) consistency of results with results of studies
with different design and different populations, (iv) dose-
response relationship, (v) biological plausibility of clinical
effects.
Condition (i) was fulfilled in most studies reported
above and condition (ii) in all of them. According to the
considerations in the previous section, condition (iii) was
also fulfilled. There was no explicit evidence for (iv) and,
up until now, no explicitly empirically validated theory
for (v). Hence, there is some evidence for a causal rela-
tionship between the therapy with Iscador and effects on
survival; at least, there is absolutely no evidence against
the hypothesis of such a causal relationship.
Tolerability and Safety
The documentation of unintended adverse drug reactions
of a therapy with Iscador has not been part of the design
of these studies. However, there is no evidence for severe
adverse effects that can plausibly be related to this
therapy [see the overviews (3,46,47)]. This has also been
supported by newer data on the tolerability and safety of
a complementary therapy with Iscador in the treatment
of breast cancer (39). In addition, apart from its effects
on the prolongation of survival and the delay of tumor
progression, mistletoe therapies reduce the side effects of
conventional chemotherapy of gynecological cancers
(15,16,39,41) that is, this type of complementary therapy
helps patients to achieve a better quality of life, despite
the impairments of chemotherapy.
Conclusions
The consistency of results across randomized and non-
randomized studies, as well as across different types of
analyses, gives some evidence that a long-term therapy
164 Therapy of breast cancer patients with Iscadorwith mistletoe preparations, particularly Iscador, has a
clinically relevant prolonging effect on survival. In the
short term, psychosomatic self-regulation, as a measure
of autonomous coping with the disease, increases signi-
ficantly more under Iscador therapy than under conven-
tional therapy alone. Overall, therapy with Iscador seems
to prolong survival and to improve psychosomatic self-
regulation of breast cancer patients.
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